"The Ponce De Leon Center is one of the largest, most comprehensive facilities dedicated to the treatment of advanced HIV/AIDS in the United States. Founded in 1986, the Ponce Center and its onsite affiliates provide various medical and support services to approximately 5000 eligible men, women, adolescents, and children living with HIV/AIDS. The Ponce Center integrates primary internal medicine and Infectious Disease subspecialty care in the Main, Family, and Transition Clinics. Staffed by doctors, nurse practitioners and physician assistants, nurses, and more than 100 interagency staff. Our care teams seamlessly provide onsite medical, support, and community services."

During the past decade, The Ponce de Leon Center CRS conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 18 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 9 clinical trials were completed. i.e. 56.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Ponce de Leon Center CRS" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 35 trials, followed by "AIDS Clinical Trials Group" with 19 trials sponsored, "Emory University" with 14 trials sponsored, "COVID-19 Prevention Network" with 2 trials sponsored and "HIV Prevention Trials Network" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Ponce de Leon Center CRS" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 25 trials as a collaborator, "AIDS Clinical Trials Group" with 5 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator and "National Institutes of Health (NIH)" with 3 trials as a collaborator. Other collaborators include 32 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "The Ponce de Leon Center CRS" are "HIV Infections" (46 trials), "HIV" (9 trials), "HIV-1 Infection" (9 trials), "HIV Infection" (5 trials) and "COVID-19" (3 trials). Many other conditions were trialed in "The Ponce de Leon Center CRS" in a lesser frequency.

Most popular intervention types in "The Ponce de Leon Center CRS" are "Drug" (56 trials), "Biological" (10 trials), "Behavioral" (6 trials), "Other" (5 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Lamivudine" (6 trials), "Ritonavir" (6 trials), "Atazanavir" (4 trials) and "Darunavir" (4 trials). Other intervention names were less common.

The vast majority of trials in "The Ponce de Leon Center CRS" are 69 trials for "All" genders, 7 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are 17 active trials in "The Ponce de Leon Center CRS". 1 are not yet recruiting, 8 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 56 completed trials in The Ponce de Leon Center CRS, 2 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in The Ponce de Leon Center CRS, 8 "Phase 1" clinical trials were conducted, 31 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 13 trials that are defined as “Not Applicable".